Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression

　　Nintedanib(brand name OFEV)has emerged as one of the most prominent antifibrotic therapies in the management of pulmonary fibrosis.It is neither an antibiotic nor a symptomatic remedy for cough or dyspnea.Its primary therapeutic value lies in slowing the progressive decline of lung function and decelerating the advancement of pulmonary fibrosis.According to the U.S.FDA-approved labeling,OFEV is indicated for the treatment of adult patients with idiopathic pulmonary fibrosis(IPF),chronic fibrosing interstitial lung diseases with a progressive phenotype(PF-ILD),and systemic sclerosis-associated interstitial lung disease(SSc-ILD).

　　Mechanistically,nintedanib is classified as a multi-target tyrosine kinase inhibitor.It simultaneously modulates several growth factor receptor signaling pathways that play pivotal roles in the pathogenesis and progression of pulmonary fibrosis,including platelet-derived growth factor receptors(PDGFR),fibroblast growth factor receptors(FGFR),and vascular endothelial growth factor receptors(VEGFR).By inhibiting these critical pathways,nintedanib reduces fibroblast proliferation and migration,attenuates excessive extracellular matrix deposition,and thereby slows the ongoing fibrotic process within lung tissue.

　　It is essential to understand that"slowing fibrosis progression"does not equate to the complete reversal of established pulmonary scarring.Pulmonary fibrosis is inherently a chronic and progressive lung disease.All currently approved antifibrotic agents aim to decelerate disease progression rather than eliminate existing fibrotic lesions.Therefore,patients who do not perceive a noticeable improvement in symptoms during treatment should not conclude that the medication is ineffective.Objective assessments such as pulmonary function testing remain crucial for evaluating therapeutic response.

　　From a clinical perspective,the therapeutic scope of nintedanib has expanded beyond idiopathic pulmonary fibrosis to encompass other interstitial lung diseases characterized by progressive fibrosis.The current FDA labeling explicitly includes progressive fibrosing ILD as an approved indication.Nevertheless,pulmonary fibrosis arising from different etiologies may vary in pathological features and management strategies.The decision to initiate nintedanib therapy should be made by a specialist based on the specific disease subtype,imaging findings,and pulmonary function trajectory of each individual patient.